Share this Page:
In this interview taken from the International Kidney Cancer Symposium (IKCS) 2019 held in Miami, USA earlier this month, Dr Tian Zhang, from Duke University talks about existing and emerging immunotherapy biomarkers for kidney cancer, and the PEDIGREE study.
Dr Zhang talks about PBRM1, PD-L1, and tumour mutational burden as prognostic biomarkers, and angiogenesis, CD8-infiltrating T-cell, and their predictive ability for atezolizumab and bevacizumab.
He finishes with a description of the PEDIGREE study, a clinical trials with an adaptive design based on investigator-assessed responses every 3 months. Patients with complete responses will go on to receive nivolumab; patients with progressive disease will go on to receive cabozantinib. Then, everyone with non-complete response or progression of disease will be randomised to either receiving nivolumab or nivolumab with cabozantinib and then followed. The primary endpoint of the trial is around overall survival at 3 years.
